ES302: Next-Generation Bispecific Antibody for IBD Therapy
Our innovative TL1A and IL23p19 bispecific antibody represents a dual-targeting approach in the treatment of inflammatory bowel disease (IBD). Currently in the preclinical stage, this molecule is designed to simultaneously block two critical cytokine pathways, offering high potency and enhanced therapeutic efficacy. Engineered for subcutaneous administration, it boasts a long-acting profile and superior resistance to enzymatic degradation, ensuring sustained therapeutic action. By targeting both TL1A and IL23p19, our bispecific antibody aims to provide a more comprehensive and effective treatment option for patients with IBD, addressing the complex pathophysiology of the disease.